Drugs /

tsma-based slp vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A personalized peptide vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. A patient's tumor is isolated, TSMAs are identified, assessed and prioritized, and two or more TSMAs are selected to be further processed into SLPs. Upon administration, personalized SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells.

Clinical Trials

View Clinical Trials for tsma-based slp vaccine

Tsma-based slp vaccine has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating tsma-based slp vaccine, 1 is phase 1 (0 open) and 1 is phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for tsma-based slp vaccine clinical trials.

Brain neoplasm and breast carcinoma are the most common diseases being investigated in tsma-based slp vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tsma-Based Slp Vaccine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tsma-Based Slp Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tsma-based slp vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
personalized synthetic long peptide vaccine, tumor specific mutant antigen-based synthetic long peptide vaccine, tsma-based synthetic long peptide vaccine, tsma-based slp vaccine, personalized slp vaccine
NCIT ID [1]:
C150471

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.